Efficacy and tolerability of rituximab and reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy for elderly patient with diffuse large B-cell lymphoma

References

• Shah BK, Bista A, Shafii B. Survival in advanced diffuse large B-cell lymphoma in pre- and post-rituximab eras in the United States. Anticancer Res. 2014 Sep;34(9):5117–5120. PubMed PMID: 25202101.
   PubMed Web of Science ®Google Scholar
• Yancik R, Ries LA. Cancer in older persons: an international issue in an aging world. Semin Oncol. 2004;31(2):128–136. PubMed PMID: 15112144. doi: 10.1053/j.seminoncol.2003.12.024
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–242. PubMed PMID: 11807147. doi: 10.1056/NEJMoa011795
   PubMed Web of Science ®Google Scholar
• Wunderlich A, Kloess M, Reiser M, et al. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol. 2003;14(6):881–893. PubMed PMID: 12796026. doi: 10.1093/annonc/mdg249
   PubMed Web of Science ®Google Scholar
• Peters FP, Fickers MM, Erdkamp FL, et al. The effect of optimal treatment on elderly patients with aggressive non-Hodgkin's lymphoma: more patients treated with unaffected response rates. Ann Hematol. 2001;80(7):406–410. PubMed PMID: 11529466. doi: 10.1007/s002770100315
   PubMed Web of Science ®Google Scholar
• Janssen-Heijnen ML, van Spronsen DJ, Lemmens VE, et al. A population-based study of severity of comorbidity among patients with non-Hodgkin's lymphoma: prognostic impact independent of International Prognostic Index. Br J Haematol. 2005;129(5):597–606. PubMed PMID: 15916681. doi: 10.1111/j.1365-2141.2005.05508.x
   PubMed Web of Science ®Google Scholar
• Aoki K, Takahashi T, Tabata S, et al. Efficacy and tolerability of reduced-dose 21-day cycle rituximab and cyclophosphamide, doxorubicin, vincristine and prednisolone therapy for elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2013;54(11):2441–2447. PubMed PMID: 23452117. doi: 10.3109/10428194.2013.780654
   PubMed Web of Science ®Google Scholar
• Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857–1861. PubMed PMID: 17105812. doi: 10.1182/blood-2006-08-038257
   PubMed Web of Science ®Google Scholar
• Meguro A, Ozaki K, Sato K, et al. Rituximab plus 70% cyclophosphamide, doxorubicin, vincristine and prednisone for Japanese patients with diffuse large B-cell lymphoma aged 70 years and older. Leuk Lymphoma. 2012;53(1):43–49. PubMed PMID: 21864040. doi: 10.3109/10428194.2011.600486
   PubMed Web of Science ®Google Scholar
• Merli F, Luminari S, Rossi G, et al. Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly “fit” patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi. Leuk Lymphoma. 2012;53(4):581–588. PubMed PMID: 21895543. doi: 10.3109/10428194.2011.621565
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005;23(18):4117–4126. PubMed PMID: 15867204. doi: 10.1200/JCO.2005.09.131
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9(2):105–116. PubMed PMID: 18226581. doi: 10.1016/S1470-2045(08)70002-0
   PubMed Web of Science ®Google Scholar
• Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649–655. PubMed PMID: 7165009. doi: 10.1097/00000421-198212000-00014
   PubMed Web of Science ®Google Scholar
• Mori M, Niitsu N, Takagi T, et al. Reduced-dose chop therapy for elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma. 2001;41(3-4):359–366. PubMed PMID: 11378549. doi: 10.3109/10428190109057991
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–586. PubMed PMID: 17242396. doi: 10.1200/JCO.2006.09.2403
   PubMed Web of Science ®Google Scholar
• Coiffier B. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma. Semin Oncol. 2002;29(2 Suppl 6):18–22. PubMed PMID: 12040530. doi: 10.1053/sonc.2002.32749
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244. PubMed PMID: 10561185. doi: 10.1200/JCO.1999.17.4.1244
   PubMed Web of Science ®Google Scholar
• Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452–458. PubMed PMID: 23208313; PubMed Central PMCID: PMCPMC3590441. doi: 10.1038/bmt.2012.244
   PubMed Web of Science ®Google Scholar
• Advani RH, Chen H, Habermann TM, et al. Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI). Br J Haematol. 2010;151(2):143–151. PubMed PMID: 20735398; PubMed Central PMCID: PMCPMC3615251. doi: 10.1111/j.1365-2141.2010.08331.x
   PubMed Web of Science ®Google Scholar
• Shin HJ, Chung JS, Song MK, et al. Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma. Cancer Chemother Pharmacol. 2012;69(5):1165–1172. PubMed PMID: 22215473. doi: 10.1007/s00280-011-1814-6
   PubMed Web of Science ®Google Scholar
• Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2011;12(5):460–468. PubMed PMID: 21482186. doi: 10.1016/S1470-2045(11)70069-9
   PubMed Web of Science ®Google Scholar